Unterstützung und Quellen
Wir verweisen auf Organisationen und veröffentlichte Quellen, denen wir vertrauen. igg4.org ist unabhängig, ohne Industriefinanzierung oder Sponsor. Eine Nennung hier ist eine Anerkennung, kein Türwächter.
Wichtige medizinische Literatur
Die veröffentlichten Quellen hinter dieser Website. Wo möglich verlinken wir eine vollständig lesbare Version, sonst den Publikationsnachweis. Dies ist Information und ersetzt nicht Ihre Fachperson.
1.Della-Torre E, Talarico R, Ballarin J, et al. Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework. Lancet Rheumatol 2025;7(1):e64-e71
Quelle lesen2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72(1):7-19
Quelle lesen3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract 2024;8(2):rkae020
Quelle lesen4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open 2019;4(Suppl 1):e000787
Quelle lesen5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics 2025;15(18):2299
Quelle lesen6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology 2020;59(Suppl 3):iii123-iii131
Quelle lesen7.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67(7):1688-1699
Quelle lesen8.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.
Quelle lesen9.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database Syst Rev 2025;(8):CD016094
Quelle lesen10.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.
Quelle lesen11.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.
Quelle lesen12.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.
Quelle lesen13.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.
Quelle lesen14.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Semin Diagn Pathol 2024;41(2):45-53
Quelle lesen15.Reisch M, Spindelböck WJ, Hodl I, Pietsch D, Rainer F, Kickinger D, Sutic A, Thiel J, Stradner M. Azathioprine as maintenance therapy for IgG4-related diseases. Rheumatology International 2026;46(3):47.
Quelle lesen16.Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease: a retrospective single-center cohort study focusing on rituximab. Rheumatology International 2026;46:33.
Quelle lesen17.Taranto S, Bernardo L, Mauro A, Perrone A, Tamborino A, Giani T. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges. Children (Basel) 2025;12(7):888.
Quelle lesen18.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).
Quelle lesen19.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.
Quelle lesen20.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.
Quelle lesen21.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.
Quelle lesen22.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.
Quelle lesen23.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther 2026;28(1):96
Quelle lesen24.Della-Torre E, Baker MC, Zhang W, et al; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med, published online 2 June 2026.
Quelle lesen25.Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Annals of the Rheumatic Diseases, 2026.
Quelle lesen26.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.
Quelle lesen27.Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab 2024;109(7):1657-1683
Quelle lesen28.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013;99(3):277-280
Quelle lesen29.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.
Quelle lesen30.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(1):236-245
Quelle lesen31.Mahajan A, Tinianow A, Katz G. IgG4-Related disease: From diagnosis to remission. Best Practice & Research Clinical Rheumatology 2025;39:102108.
Quelle lesen32.Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis 2024;83(5):651-660
Quelle lesen33.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, European Alliance of Associations for Rheumatology
Quelle lesen34.Choosing Wisely Canada, Allergy and Clinical Immunology recommendations, Canadian Society of Allergy and Clinical Immunology, updated May 2025
Quelle lesen35.Yang F, Wang T, Liu Y. Risk factors for relapse of IgG4-related disease: a systematic review and meta-analysis. Clin Rheumatol 2025;44:4137-4147
Quelle lesen36.Angarola E, Pasqua A, Castro HM, Cáceres A, Spina JC, Casciato P. Clinical characteristics, disease course, and chronic organ damage in a real-world cohort of IgG4-related disease: insights from an Interdisciplinary Unit. Medicina Clínica 2026;166:107317
Quelle lesen37.Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 2025;157:103487
Quelle lesen38.Koster MJ, Ghaffar U, Duong SQ, et al. Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clin Exp Rheumatol 2022;40:751-757
Quelle lesen39.Dattani R, Barwick TD, El Wardany G, et al; RaDaR Rare Disease Group. An international patient-centred study of retroperitoneal fibrosis. QJM 2022;115(3):148-154
Quelle lesen40.Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910
Quelle lesen41.So H, Choi SJ, Park S, et al. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021. Sci Rep 2025;15:37273
Quelle lesen42.American College of Rheumatology. IgG4-Related Disease (IgG4-RD). Patient information page, updated February 2025.
Quelle lesen43.Gwozdz-Broczkowska A. Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework. Rheumatol Int 2026;46(8):232.
Quelle lesen44.US Food and Drug Administration. RAYOS (prednisone) delayed-release tablets, prescribing information, revision 12/2019.
Quelle lesen45.Liu Q, Zheng Y, Sturmlechner I, et al. IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease. J Clin Invest 2024;134(16):e178692.
Quelle lesen46.FAI2R. Maladie associee aux IgG4: les reponses a vos questions.
Quelle lesen47.Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62(4):e48-e88.
Quelle lesen48.European Medicines Agency. MabThera (rituximab), Summary of Product Characteristics.
Quelle lesen49.European Medicines Agency. Nordimet (methotrexate), Summary of Product Characteristics.
Quelle lesen50.US Food and Drug Administration. IMURAN (azathioprine) 50-mg scored tablets, product information, revision 12/2018.
Quelle lesen51.Yu K, Gao H, Liu S, et al. Perception of recurrence risk in patients with IgG4-related disease: a descriptive phenomenological study. Rheumatol Adv Pract 2025;9(1):rkae148.
Quelle lesen52.Newman JH, Shaver A, Sheehan JH, et al; Undiagnosed Disease Network. IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med 2019;7(6):e686.
Quelle lesen53.Karamya ZA, Kovacs A, Illes D, Czako B, Fazekas A, Farkas N, Hegyi P, Czako L. Prevalence of autoimmune pancreatitis in pancreatic resection for suspected malignancy: a systematic review and meta-analysis. BMC Gastroenterol 2024;24:278.
Quelle lesen54.Dures E, Farisogullari B, Santos EJF, et al. 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2024;83(10):1260-1267.
Quelle lesen55.Motor J, Gajewska A, Cienkowski K, et al. IgG4-related disease: focus on digestive system involvement. Front Immunol 2025;16:1584107.
Quelle lesen56.Orphanet. Enfermedad sistemica relacionada con IgG4 (ORPHA:596448), Spanish version.
Quelle lesen57.Orphanet. IgG4-gerelateerde systemische ziekte (ORPHA:596448), Dutch version.
Quelle lesen58.Orphanet. Maladie systemique liee a la presence d'anticorps IgG4 (ORPHA:596448), French version.
Quelle lesen59.Orphanet. IgG4-related systemic disease (ORPHA:596448), German version.
Quelle lesen60.European Medicines Agency. Uplizna (inebilizumab), European public assessment report.
Quelle lesen61.Erasmus MC. IgG4-gerelateerde ziekte, patient information.
Quelle lesen62.Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74(6):1171-1177.
Quelle lesen63.Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 2017;12(9):e0183844.
Quelle lesen64.ClinicalTrials.gov registry record NCT04520451. An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Participants With IgG4-Related Disease. Phase 2, completed. Sponsor: Principia Biopharma, a Sanofi Company.
Quelle lesen65.ClinicalTrials.gov registry record NCT07190196. A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease (RILIEF). Recruiting. Sponsor: Sanofi.
Quelle lesen66.Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, Kleine-Tebbe J; EAACI Task Force. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008;63(7):793-796.
Quelle lesen67.Orphanet. IgG4-related systemic disease (ORPHA:596448).
Quelle lesen68.Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS). Ficha tecnica prednisona, CIMA.
Quelle lesen69.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4. Haute Autorite de Sante, with FAI2R and CERAINOM-IgG4, November 2025.
Quelle lesen70.Het Oogziekenhuis Rotterdam. IgG4-gerelateerde orbitale ziekte, patient information.
Quelle lesen71.Imperial College Healthcare NHS Trust. RPF and IgG4-RD (retroperitoneal fibrosis and immunoglobulin-4 related disease), specialist nephrology service.
Quelle lesen
National clinical guidance
Die folgenden Links führen aus dieser Website heraus, um Ihnen die eigene Suche zu erleichtern. Wir kontrollieren sie nicht und empfehlen sie nicht, und wir haben keinen Vorteil davon, sie aufzuführen. Anders als unsere eigenen Quellen oben werden sie von uns nicht auf Herkunft oder Richtigkeit geprüft. Bestätigen Sie Wichtiges immer mit Ihrer Fachperson.
1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.
Quelle lesen
Product information (regulatory)
Die folgenden Links führen aus dieser Website heraus, um Ihnen die eigene Suche zu erleichtern. Wir kontrollieren sie nicht und empfehlen sie nicht, und wir haben keinen Vorteil davon, sie aufzuführen. Anders als unsere eigenen Quellen oben werden sie von uns nicht auf Herkunft oder Richtigkeit geprüft. Bestätigen Sie Wichtiges immer mit Ihrer Fachperson.
1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA
Quelle lesen
Patient information from specialist centres
Die folgenden Links führen aus dieser Website heraus, um Ihnen die eigene Suche zu erleichtern. Wir kontrollieren sie nicht und empfehlen sie nicht, und wir haben keinen Vorteil davon, sie aufzuführen. Anders als unsere eigenen Quellen oben werden sie von uns nicht auf Herkunft oder Richtigkeit geprüft. Bestätigen Sie Wichtiges immer mit Ihrer Fachperson.
1.Het Oogziekenhuis Rotterdam, IgG4-Gerelateerde Orbitale Ziekte (IgG4-related orbital disease), patient information. Recognised Dutch expertise centre for rare orbital conditions.
Quelle lesen2.Imperial College Healthcare NHS Trust, RPF and IgG4-RD service: specialist multidisciplinary service for retroperitoneal fibrosis and IgG4-related disease.
Quelle lesen
Nützliche Websites
Die folgenden Links führen aus dieser Website heraus, um Ihnen die eigene Suche zu erleichtern. Wir kontrollieren sie nicht und empfehlen sie nicht, und wir haben keinen Vorteil davon, sie aufzuführen. Anders als unsere eigenen Quellen oben werden sie von uns nicht auf Herkunft oder Richtigkeit geprüft. Bestätigen Sie Wichtiges immer mit Ihrer Fachperson.
- European Federation for IgG4-related disease
- IgG4ward! Foundation
- IgG4ward! Academy (online learning course)
- Asociación Española de Pacientes con Enfermedad Relacionada con IgG4 (AE-IgG4)
- Association Française du Syndrome et de la maladie associée aux IgG4 (AFRIGG4)
- Cleveland Clinic — IgG4-related disease
- MedLink Neurology — IgG4-related disease: neurological manifestations
- Orphanet, the portal for rare diseases: IgG4-related systemic disease (ORPHA:596448)
- ERN ReCONNET — IgG4-related disease (European Reference Network)
- Massachusetts General Hospital — IgG4-Related Systemic Disease Program
- FAI2R — Maladie associée aux IgG4 (réseau français des maladies rares, espace patients)
- IgG4-Syndrom — Uniklinikum Erlangen (Patienteninformation)
- ZIPSE — Zentrales Informationsportal über seltene Erkrankungen: IgG4-assoziierte Erkrankung
- FEDER — Enfermedad asociada a IgG4 (Federación Española de Enfermedades Raras)
Dieser Assistent teilt belegte Informationen und kann Sie nicht diagnostizieren oder Ihre Ärztin oder Ihren Arzt ersetzen. Suchen Sie im Notfall zuerst dringende Hilfe.
